Earnings Call · Q1 FY2022·2022-05-05

Q1 22EPS -3.45%·Rev n/aQ4 21EPS +25.71%·Rev n/aQ3 21EPS 0.00%·Rev n/aQ2 21EPS -6.45%·Rev n/a⚠ consensus missing

SANGAMO THERAPEUTICS, INC SGMO

Louise Wilkie — Investor Relations

Sandy Macrae — Chief Executive Officer

Rob Schott — Head of Development

Jason Fontenot — Chief Scientific Officer

Prathyusha Duraibabu — Chief Financial Officer

−3.7%1d on move date−3.1% vs SPY3d−10.0%5d−12.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SGMO calls or request research access.

More SGMO calls Browse calls Request research access